2023 World Conference on Lung Cancer (Posters)-EP12.01. Predictive and Prognostic Value of Early Skeletal Muscle Loss during First-Line EGFR-TKIs for Advanced Lung Adenocarcinoma

EP12.01. Predictive and Prognostic Value of Early Skeletal Muscle Loss during First-Line EGFR-TKIs for Advanced Lung Adenocarcinoma - PDF(Abstract)

Back to course

Pdf Summary

This study investigated the predictive and prognostic value of early skeletal muscle loss during first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment for advanced lung adenocarcinoma. The study retrospectively evaluated 104 patients with EGFR-mutant advanced lung adenocarcinoma treated with icotinib or afatinib between 2016 and 2020. Skeletal muscle mass was measured using abdominal computed tomography scans obtained before and during EGFR-TKIs treatment. Muscle changes were categorized into muscle loss and muscle stable groups. <br /><br />The study found that 40.4% of patients experienced muscle loss, with a median reduction rate of 2.9%. Patients with low muscle density before treatment and those who experienced Grade 2 diarrhea during treatment were more likely to suffer from muscle loss. The median progression-free survival (PFS) was shorter for the muscle loss group compared to the muscle stable group. Early muscle loss during treatment, rather than baseline low muscle mass or muscle density, was independently associated with shorter PFS of first-line EGFR-TKIs treatment. <br /><br />The study also found that fewer patients in the muscle loss group received chemotherapy after the progression of first-line EGFR-TKIs treatment. Additionally, the muscle loss group had shorter median overall survival compared to the muscle stable group. <br /><br />These findings suggest that early skeletal muscle loss is associated with limited survival benefits of EGFR-TKIs treatment for advanced lung adenocarcinoma patients. The study recommends further research to investigate strategies for maintaining muscle mass during EGFR-TKIs treatment.

Asset Subtitle

Xin Nie

Meta Tag

Speaker Xin Nie

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

skeletal muscle loss

epidermal growth factor receptor

tyrosine kinase inhibitors

lung adenocarcinoma

icotinib

afatinib

muscle density

diarrhea

progression-free survival

chemotherapy